Chronic Lower Back Pain Global Market Report 2025

Chronic low back pain (CLBP) characterizes pain persisting for 12 weeks or more, despite treatment aimed at resolving the initial cause or acute episode of low back pain. This condition represents a major contributor to disability and often gives rise to psychological issues such as stress, depression, and anxiety.

The primary types of chronic lower back pain encompass discogenic pain, lumbar spinal stenosis, sacroiliac pain, facet-joint pain, radicular pain, muscular pain, and other variants. Discogenic pain specifically originates from damage to spinal discs, commonly associated with conditions such as degenerative disc disease, which occurs naturally as part of the aging process. Diagnosis typically involves a comprehensive clinical history, physical examination, imaging assessments, and pain evaluation. Treatment is administered across various healthcare facilities, including hospitals, orthopedic clinics, ambulatory surgery centers, among others.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The chronic lower back pain market research report is one of a series of new reports from The Business Research Company that provides chronic lower back pain market statistics, including chronic lower back pain industry global market size, regional shares, competitors with a chronic lower back pain market share, detailed chronic lower back pain market segments, market trends and opportunities, and any further data you may need to thrive in the chronic lower back pain industry. This chronic lower back pain market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The chronic lower back pain market size has grown steadily in recent years. It will grow from $7.72 billion in 2024 to $8.04 billion in 2025 at a compound annual growth rate (CAGR) of 4.1%. The growth in the historic period can be attributed to sedentary lifestyles, manual labor and occupational risks, medical advancements in diagnosis, pain management evolution, epidemiological studies.

The chronic lower back pain market size is expected to see steady growth in the next few years. It will grow to $9.63 billion in 2029 at a compound annual growth rate (CAGR) of 4.6%. The growth in the forecast period can be attributed to rise in non-pharmacological interventions, preventive healthcare initiatives, focus on holistic treatments, regenerative medicine development, aging population trends. Major trends in the forecast period include focus on non-pharmacological interventions, shift in pain management approaches, healthcare awareness and education, telemedicine and remote monitoring, integration of regenerative medicine.

The forecast of 4.6% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may pose challenges for U.S. pain management by restricting access to spinal cord stimulators and biologic disc repair materials imported from Belgium and Sweden, potentially reducing treatment efficacy and increasing rehabilitation costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The chronic lower back pain market is expected to witness growth driven by an increase in the frequency of nerve instances. In this context, nerve instances refer to specific occurrences where individuals display bravery, courage, or resilience in challenging situations. Continuous exposure to stress and pain can lead to central sensitization, a phenomenon where the nervous system becomes hypersensitive, intensifying the perception of pain even in the absence of actual injury. As reported by Nature in July 2023, the prevalence of peripheral neuropathy, associated with nerve damage, is 28.4% in adults aged 40 or older with diabetes and 11.8% in those without diabetes. The rising frequency of nerve instances contributes to the growth of the chronic lower back pain market.

An increase in the geriatric population is projected to drive the growth of the chronic lower back pain market in the future. The geriatric population refers to individuals aged 65 and older. In this demographic, age-related neurodegenerative and musculoskeletal conditions, such as arthritis and osteoarthritis, tend to progress rapidly, resulting in weakness and painful complaints that contribute to chronic back pain and decreased physical activity. For example, in May 2024, the Administration for Community Living, a US-based government agency, reported that in 2022, 17.3% of the population was 65 or older. This percentage is anticipated to rise to 22% by 2040. Consequently, the growth of the geriatric population is fueling the expansion of the chronic lower back pain market.

Technological advancements emerge as a key trend gaining popularity in the chronic lower back pain market. Major companies within this market are actively involved in developing new and improved advanced technologies for the treatment and prevention of lower back pain to maintain their competitive positions. In December 2022, Abbott Laboratories, a US-based medical devices and healthcare company, introduced the Eterna spinal cord stimulation (SCS) device. Recognized as the world's smallest implantable, rechargeable spinal cord stimulator for treating chronic pain, the Eterna SCS device, featuring Abbott's low-dose BurstDR stimulation technology, has received approval from the US Food and Drug Administration (FDA). This technological innovation demonstrates the commitment of major companies to advancing the treatment options for chronic lower back pain.

Major companies in the chronic lower back pain market are actively engaged in the development of products incorporating advanced technologies, such as BurstDR SCS technology, to introduce innovative options for patients. BurstDR SCS technology is a proprietary therapy within the spinal cord stimulation (SCS) category, employing mild electrical pulses to modify pain signals during their transmission from the spinal cord to the brain. An illustration of this technological advancement is evident in the case of Abbott Laboratories, a prominent US-based medical device company. In May 2023, Abbott Laboratories received approval from the US Food and Drug Administration (FDA) for its Spinal Cord Stimulation (SCS) devices, which include the Proclaim SCS Family and Eterna SCS System specifically designed for treating chronic back pain. Abbott's SCS devices utilize the proprietary BurstDR stimulation waveform, offering a superior therapy that closely replicates the pathway of pain signals to the brain, effectively addressing the emotional aspects associated with pain. This stands in contrast to traditional tonic stimulation methods.

In November 2023, Boston Scientific, a US-based biotechnology engineering firm, acquired Relievant Medsystems, Inc. for $850 million. This acquisition strengthens Boston Scientific's portfolio in chronic pain management by integrating Relievant's Intracept intraosseous nerve ablation system, which is specifically designed to address vertebrogenic pain, a type of chronic lower back pain. Relievant Medsystems, Inc. is a US-based manufacturer of medical equipment.

Major companies operating in the chronic lower back pain market include Pfizer Inc., Johnson & Johnson Private Limited, Sanofi S.A., Endo Pharmaceuticals plc, Merck Corporation, Vertebral Technologies Inc., Medtronic plc, Boston Scientific Corporation, BioWave Corporation, Koninklijke Philips N.V., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., SpineThera Inc., Dr. Reddy's Laboratories Ltd., Celgene Corporation, Axsome Therapeutics Inc., Mesoblast Limited, Frontier Biotechnologies Inc., Eli Lilly and Company, Persica Pharmaceuticals, Abbott Laboratories, Hisamitsu Pharmaceutical Co. Inc., Ipsen S.A., Daiichi Sankyo Company Ltd., Zimmer Biomet Holdings Inc., Novartis International AG, Janssen Pharmaceuticals Inc., Insys Therapeutics Inc., Collegium Pharmaceutical Inc., Cara Therapeutics Inc.

North America was the largest region in the chronic lower back pain market in 2024. The regions covered in the chronic lower back pain market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the chronic lower back pain market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The chronic low back pain market includes revenues earned by entities by providing low back pain treatment services such as pain management services, and neuropathic and nociceptive pain management. Establishments that provide long treatment plans and management services are included in this market. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Chronic Lower Back Pain Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on chronic lower back pain market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for chronic lower back pain ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The chronic lower back pain market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type Of Pain: Diskogenic Pain; Lumbar Spinal Stenosis; Sacroiliac Pain; Facet-Joint Pain; Radicular Pain; Muscular Pain; Other Types Of Pain
• 2) By Diagnosis: Clinical History; Physical Examination; Imaging Guidelines; Assessment Of Pain
• 3) By End-User: Hospitals; Orthopedic Clinics; Ambulatory Surgery Centers; Other End-Users
• Subsegments:
• 1) By Diskogenic Pain: Herniated Disc; Degenerative Disc Disease; Disc Bulge; Lumbar Spinal Stenosis
• 2) By Lumbar Spinal Stenosis: Central Stenosis; Lateral Stenosis
• 3) By Sacroiliac Pain: Sacroiliac Joint Dysfunction; Inflammatory Conditions
• 4) By Facet-Joint Pain: Facet Joint Syndrome; Osteoarthritis Of The Facet Joints
• 5) By Radicular Pain: Sciatica; Nerve Root Compression
• 6) By Muscular Pain: Muscle Strain; Muscle Spasm
• 7) By Other Types of Pain: Myofascial Pain Syndrome; Spondylolisthesis; Osteoporosis-Related Pain
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson Private Limited; Sanofi S.A.; Endo Pharmaceuticals plc; Merck Corporation; Vertebral Technologies Inc.; Medtronic plc; Boston Scientific Corporation; BioWave Corporation; Koninklijke Philips N.V.; Teva Pharmaceutical Industries Ltd.; Astellas Pharma Inc.; SpineThera Inc.; Dr. Reddy's Laboratories Ltd.; Celgene Corporation; Axsome Therapeutics Inc.; Mesoblast Limited; Frontier Biotechnologies Inc.; Eli Lilly and Company; Persica Pharmaceuticals; Abbott Laboratories; Hisamitsu Pharmaceutical Co. Inc.; Ipsen S.A.; Daiichi Sankyo Company Ltd.; Zimmer Biomet Holdings Inc.; Novartis International AG; Janssen Pharmaceuticals Inc.; Insys Therapeutics Inc.; Collegium Pharmaceutical Inc.; Cara Therapeutics Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.